key: cord-0762790-vqwfy7a8
authors: Valcourt, Emelissa J.; Manguiat, Kathy; Robinson, Alyssia; Lin, Yi-Chan; Abe, Kento T.; Mubareka, Samira; Shigayeva, Altynay; Zhong, Zoë; Girardin, Roxie C.; DuPuis, Alan; Payne, Anne; McDonough, Kathleen; Wang, Zhen; Gasser, Romain; Laumaea, Annemarie; Benlarbi, Mehdi; Richard, Jonathan; Prévost, Jérémie; Anand, Sai Priya; Dimitrova, Kristina; Phillipson, Clark; McGeer, Allison; Gingras, Anne-Claude; Liang, Chen; Petric, Martin; Sekirov, Inna; Morshed, Muhammad; Finzi, Andrés; Drebot, Michael; Wood, Heidi
title: Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays
date: 2021-11-17
journal: Microbiol Spectr
DOI: 10.1128/spectrum.00886-21
sha: bababb96ae64bc565c6ef976dc3796aa8430ffbf
doc_id: 762790
cord_uid: vqwfy7a8

The evaluation of humoral protective immunity against SARS-CoV-2 remains crucial in understanding both natural immunity and protective immunity conferred by the several vaccines implemented in the fight against COVID-19. The reference standard for the quantification of antibodies capable of neutralizing SARS-CoV-2 is the plaque-reduction neutralization test (PRNT). However, given that it is a laboratory-developed assay, validation is crucial in order to ensure sufficient specificity and intra- and interassay precision. In addition, a multitude of other serological assays have been developed, including enzyme-linked immunosorbent assay (ELISA), flow cytometry-based assays, luciferase-based lentiviral pseudotype assays, and commercially available human ACE2 receptor-blocking antibody tests, which offer practical advantages in the evaluation of the protective humoral response against SARS-CoV-2. In this study, we validated a SARS-CoV-2 PRNT to assess both 50% and 90% neutralization of SARS-CoV-2 according to guidelines outlined by the World Health Organization. Upon validation, the reference-standard PRNT demonstrated excellent specificity and both intra- and interassay precision. Using the validated assay as a reference standard, we characterized the neutralizing antibody response in specimens from patients with laboratory-confirmed COVID-19. Finally, we conducted a small-scale multilaboratory comparison of alternate SARS-CoV-2 PRNTs and surrogate neutralization tests. These assays demonstrated substantial to perfect interrater agreement with the reference-standard PRNT and offer useful alternatives to assess humoral immunity against SARS-CoV-2. IMPORTANCE SARS-CoV-2, the causal agent of COVID-19, has infected over 246 million people and led to over 5 million deaths as of October 2021. With the approval of several efficacious COVID-19 vaccines, methods to evaluate protective immune responses will be crucial for the understanding of long-term immunity in the rapidly growing vaccinated population. The PRNT, which quantifies SARS-CoV-2-neutralizing antibodies, is used widely as a reference standard to validate new platforms but has not undergone substantial validation to ensure excellent inter- and intraassay precision and specificity. Our work is significant, as it describes the thorough validation of a PRNT, which we then used as a reference standard for the comparison of several alternative serological methods to measure SARS-CoV-2-neutralizing antibodies. These assays demonstrated excellent agreement with the reference-standard PRNT and include high-throughput platforms, which can greatly enhance capacity to assess both natural and vaccine-induced protective immunity against SARS-CoV-2.

of several efficacious COVID-19 vaccines, methods to evaluate protective immune responses will be crucial for the understanding of long-term immunity in the rapidly growing vaccinated population. The PRNT, which quantifies SARS-CoV-2-neutralizing antibodies, is used widely as a reference standard to validate new platforms but has not undergone substantial validation to ensure excellent inter-and intraassay precision and specificity. Our work is significant, as it describes the thorough validation of a PRNT, which we then used as a reference standard for the comparison of several alternative serological methods to measure SARS-CoV-2-neutralizing antibodies. These assays demonstrated excellent agreement with the reference-standard PRNT and include high-throughput platforms, which can greatly enhance capacity to assess both natural and vaccine-induced protective immunity against SARS-CoV-2.

KEYWORDS COVID-19, immunity, SARS-CoV-2, immunoserology, neutralizing antibodies S ince its emergence in December 2019, the coronavirus disease 2019 (COVID-19) pandemic has caused millions of cases and fatalities worldwide (https://www.who.int/ news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regu lations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov); https://www.who.int/publications/m/item/weekly-epidemiological-update -on-covid-19-26-october-2021). Mitigating transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has proven extremely difficult due to presymptomatic viral shedding (1) and the long infectious period of a large portion of asymptomatically infected individuals (2) . These factors severely hinder case detection, self-isolation, and quarantine (3) . Studies showed that some immune responses, including viral neutralization, decrease within weeks of infection in both symptomatic and asymptomatic individuals (2, (4) (5) (6) (7) . However, additional immune responses, including Fc-mediated effector functions, T cell immunity responses, and memory B cell responses, remain detectable for at least 5 months postinfection (8) (9) (10) . With success of several vaccines in clinical trials (11, 12) , as well as hundreds of other vaccine candidates in different stages of development (13, 14) , the implications of waning immunity on long-term vaccinemediated protection will require further investigation. In order to do so, a means to quantify humoral protective immunity to SARS-CoV-2 will be indispensable.

Several laboratory-developed (5, 6, 15) and commercially available (16) enzyme-linked immunosorbent assays (ELISAs) have been developed to detect anti-SARS-CoV-2 antibodies raised upon infection. While these platforms provide a high-throughput means of detecting antibodies against SARS-CoV-2, they are unable to measure the immunological function of SARS-CoV-2-specific antibodies. In contrast, the plaque-reduction neutralization test (PRNT) quantifies levels of neutralizing antibodies capable of blocking the interaction that mediates virus entry into susceptible host cells and subsequent virus replication. For SARS-CoV-2, this interaction involves binding of the receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein with the angiotensin-converting enzyme 2 (ACE2) (17) . Antibodies targeting non-RBD epitopes of SARS-CoV-2 have also demonstrated low to high levels of neutralization activity (18) (19) (20) . While the conventional PRNT is often used as the reference standard for the evaluation of virus-neutralizing antibodies, this assay is time-consuming and laborious and requires containment level 3 (CL-3) facilities to work with the risk group-3 pathogen. In contrast, laboratory-developed and commercially available surrogate SARS-CoV-2 neutralization tests, including microneutralization and human ACE 2 receptor-blocking antibody tests, have been developed for high-throughput evaluation of functional immunity against SARS-CoV-2 and may offer advantages in large-scale immunity testing.

In this study, we aimed to validate a laboratory-developed SARS-CoV-2 PRNT to assess both 50% neutralization (PRNT-50) and 90% neutralization (PRNT-90) of SARS-CoV-2 according to guidelines outlined by the World Health Organization (https:// www.who.int/medicines/areas/quality_safety/quality_assurance/28092018Guideline_ Validation_AnalyticalMethodValidation-Appendix4_QAS16-671.pdf) and characterized the neutralizing antibody response in laboratory-confirmed COVID-19 specimens. Using the validated PRNT as a reference standard, along with a panel of characterized serological specimens, we conducted a small-scale multilaboratory comparison of alternate SARS-CoV-2 PRNTs and surrogate neutralization tests to identify other methods to assess the neutralizing antibody response in SARS-CoV-2 infection.

Neutralizing antibody responses of the laboratory-confirmed COVID-19 sample subset quantified by SARS-CoV-2 PRNT. The reference-standard PRNT was used to test a panel of specimens collected from COVID-19 patients confirmed by molecular testing. Of the laboratory-confirmed COVID-19 specimens, 82.1% and 54.1% demonstrated 50% and 90% neutralization of SARS-CoV-2 by PRNT-50 and PRNT-90, respectively ( (Fig. 1) . The average PRNT-50 titers of specimens collected between 15 and 21 days post-symptom onset were significantly higher than those of specimens collected between 1 and 7 (P , 0.0001), 8 to 14 (P , 0.0001), 29 to 35 (P = 0.0008), and $50 (P , 0.0001) days post-symptom onset, respectively.

The average reciprocal endpoint titers capable of neutralizing 90% SARS-CoV-2 were 3, 35, 98, 125, 149, 106, 26, and 102 for specimens collected at collected at 1 to 7, 8 to 14, 15 to 21, 22 to 28, 29 to 35, 36 to 42, 43 to 49, and $50 days post-symptom onset (Fig. 1) . Average PRNT-90 titers between specimens collected from laboratory-confirmed COVID-19 at different times post-symptom onset were not significantly different.

Validation of the reference standard SARS-CoV-2 PRNT. The sensitivity of the PRNT-50 and PRNT-90 for laboratory-confirmed COVID-19 specimens was 82.1% and 54.1%, respectively (Table 2 ). Both PRNT-50 and PRNT-90 demonstrated 100% specificity. Within the same assay, the PRNT-50 demonstrated excellent intraassay precision, with 100%, 100%, and 86.1% of results within 4-fold of, within 2-fold of, and equal to the median test result, respectively ( Table 3 ). The PRNT-90 also demonstrated sufficient intraassay precision, with 100%, 98.6%, and 84.7% of results within 4-fold of, within 2fold of, and equal to the median test result. Both the PRNT-50 and PRNT-90 surpassed the validation cutoff, which required $90% of results generated to be within 2-fold of the median test result (https://www.who.int/medicines/areas/quality_safety/quality_ assurance/28092018Guideline_Validation_AnalyticalMethodValidation-Appendix4_QA S16-671.pdf). The accuracy of the reference-standard PRNT when using the PRNT-50 analysis was 88.8% (51.8 to 99.7%) and thus was considered to have sufficient accuracy ( Table 2 ). The absolute differences between the log 2 observed and log 2 expected values for the first SARS-CoV-2 specimen were 0.36, 0.49, and 0.19, for 1:4, 1:16, and 1: 64 dilutions, respectively. The absolute differences between the log 2 observed and log 2 expected values for the second SARS-CoV-2 specimen were 1.81, 1.81, and 2.13, for 1:4, 1:16, and 1:64 dilutions, respectively. The absolute differences between the log 2 observed and log 2 expected values for the first SARS-CoV-2 specimen were 0.32, 0.00, and 0.00 for 1:4, 1:16, and 1:64 dilutions, respectively. However, accuracy could not be calculated for the PRNT-90 analysis since the expected titers for 1:4, 1:16, and 1:64 were below the limit of detection of the assay (1:20).

Between several assay runs, the PRNT-50 demonstrated sufficient interassay precision, with 98.2%, 98.2%, and 80.0% of results within 4-fold of, within 2-fold of, and equal to the median test result, respectively ( Table 3 ). The PRNT-90 also demonstrated sufficient interassay precision, with 98.2% and 90.7% of results within 4-fold and 2-fold of the median test result; 68.5% of results by PRNT-90 were equal to the median test result. Both the PRNT-50 and PRNT-90 surpassed the validation cutoff, which required $90% of results generated to be within 2-fold of the median test result. The referencestandard PRNT demonstrated no reactivity with the COVID-191/neutralizing antibodynegative (nAb2), SARS-CoV-1, hepatitis, HIV, syphilis, and preoutbreak sera that were used in the panel for the multilaboratory assay comparison.

Small-scale multilaboratory comparison of conventional and surrogate SARS-CoV-2 neutralization assays. Alternate PRNT conducted by University of Alberta (U of A) demonstrated 100% congruence (P , 0.0001) and perfect interrater agreement with the reference-standard PRNT (k -value 1.000) as shown in Table 4 . This assay detected 100% of laboratory-confirmed COVID-19 nAb1 specimens and did not cross-react with any specimens from the COVID-19 nAb2, SARS-CoV-1, hepatitis, HIV, or syphilis subsets. This assay also did not show any reactivity with sera collected from healthy patients prior to the COVID-19 pandemic. The alternate PRNT conducted by Wadsworth demonstrated 97.5% congruence (P , 0.0001) and almost perfect interrater agreement with the reference-standard PRNT (k -value 0.950). This assay detected 100% of laboratory-confirmed COVID-19 nAb1 specimens and did not show any reactivity with sera other than the laboratory-confirmed COVID-19 nAb2 specimen. a Due to various host responses, specimens within the molecularly confirmed COVID-19 subset may include both nAb1 and nAb2 specimens. NA, not applicable. b Sensitivity: percentage of molecularly confirmed COVID-19 specimens which tested positive by SARS-CoV-2 PRNT. c Specificity: specimens collected from healthy patients prior to the COVID-19 pandemic which tested negative by SARS-CoV-2 PRNT. d Accuracy: 3 specimens positive for SARS-CoV-2 nAbs diluted at 1:4, 1:16, and 1:64 and undiluted and tested 4 times. A result was considered accurate if the absolute difference between the log 2 expected and log 2 observed value was #2.00. Accuracy of the PRNT-90 could not be assessed since the expected titers of diluted specimens fell below the limit of detection of the assay (1:20). Number of specimens and 95% confidence intervals are indicated in parentheses.

The conventional virus neutralization test (cVNT) conducted by BC CDC demonstrated 95% congruence (P , 0.0001) and almost perfect interrater agreement with the referencestandard PRNT (k -value 0.900; Table 4 ). It detected 94.7% of laboratory-confirmed COVID-19 nAb1 specimens and the COVID-19 specimen that tested nAb2 by the reference standard also tested negative by the cVNT. The fluorescence-activated cell sorter (FACS)based surrogate virus neutralization test (sVNT) by CRCHUM was performed as described previously (6) and demonstrated 92.5% congruence (P , 0.0001) and almost perfect interrater agreement with the reference-standard PRNT (k -value 0.851). It detected 100% of laboratory-confirmed COVID-19 nAb1 specimens. However, the COVID-19 nAb2 specimen tested positive by this assay.

Luciferase-based lentivirus sVNTs performed by McGill University, CRCHUM, and Mount Sinai demonstrated 82.5% (P , 0.0001), 92.5.0% (P , 0.0001), and 85.0% (P , 0.0001) congruence with the reference-standard PRNT, respectively (Table 4 ). This corresponded with substantial, almost perfect, and substantial interrater agreement with the reference-standard PRNT (k -value 0.655, 0.849, and 0.704, respectively). These luciferase-based lentivirus sVNTs performed by McGill University and Mount Sinai detected 100% of COVID-19 nAb1 specimens. The sVNT conducted by CRCHUM detected 89.5% of COVID-19 nAb1 specimens.

The commercially available Genscript sVNT conducted by McGill University demonstrated 95% congruence (P , 0.0001) and almost perfect interrater agreement (k -value 0.900) with the reference-standard PRNT. The Genscript sVNT detected 100% of COVID-19 nAb1 specimens; the COVID-19 nAb2 specimen tested positive by this assay.

Lastly, the anti-RBD IgG ELISA conducted by CRCHUM demonstrated 97.5% congruence (P , 0.0001) and almost perfect interrater agreement (k -value 0.950) with the reference-standard PRNT. The ELISA detected 100% of COVID-19 nAb1 specimens; the COVID-19 nAb2 specimen tested negative by this assay.

The public health, economic, and societal impacts of the COVID-19 pandemic have led to expedited approval and emergency use of several promising vaccine candidates (https://www.who.int/news/item/15-02-2021-who-lists-two-additional-covid-19 -vaccines-for-emergency-use-and-covax-roll-out). However, since much remains unknown about long-term immunity against SARS-CoV-2, reliable methods to quantify functional humoral immune responses will be indispensable for understanding protection in both vaccinated and naturally infected individuals. In this study, we validated a laboratorydeveloped method of quantifying antibodies capable of neutralizing SARS-CoV-2 in vitro. The validated PRNT was used to characterize a subset of laboratory-confirmed COVID-19 serological specimens and subsequently used as a reference standard for the evaluation of other platforms for the analysis of the SARS-CoV-2-neutralizing antibody response.

In this study, 82.1% and 54.1% of laboratory-confirmed COVID-19 specimens demonstrated 50% and 90% neutralization of SARS-CoV-2. Specimens collected from 15 to 21 days post-symptom onset demonstrated the highest average PRNT-50 titers compared with those from other time points. These observations align with previous studies that have shown variability in the development, potency, and longevity of neutralizing antibody responses in COVID-19 patients (4, 8, 21). However, specimens used in this study were not collected from the same patients at each different time point. 100% (19) 94.7% (18) 100% (19) 100% (19) 89.5% (17) 100% (19) 100% (19) 100% (19) COVID-19 nAb2 (n = 1)

100% (1) 100% (1) 0% (0) 0% (0) 100% (1) 0% (0) 0% (0) 100% (1) SARS-CoV-1 (n = 2)

100% (2) 100% (2) 100% (2) 0% (0) 50% (1) 100% (2) 100% (2) 50% (1) 50% (1) Hepatitis (n = 5)

100% (5) 100% (5) 80% (4) 100% (5) 100% (5) 100% (5) 100% (5) 100% (5) 100% (5%)

100% (3) 100% (3) 100% (3) 33.3% (1) 100% (3) 100% (3) 100% (3) 100% (3) Syphilis (n = 5)

100% (5) 100% (5) 100% (5) 100% (5) 40% (2) 80% (4) 0% (0) 100% (5) 100% (5) Preoutbreak sera (n = 5)

100% (5) 100% (5) 100% (5) 100% (5) 100% (5) 100% (5) 100% (5) 100% (5) 100% (5) Total congruence (n = 40) 97.5% ( Therefore, we are unable to determine whether the lower titers observed at later time points were due to variability in individual responses within subgroups or a temporal trend in host response.

The validated PRNT in this study demonstrated excellent intraassay and interassay precision with results falling within 2-fold of the median test result. However, the proportion of results equal to the median result between assay runs was lower when using the PRNT-90 analyses. Similarly, interassay variation has been demonstrated in PRNT assays for dengue virus, which have been used for the detection of neutralizing antibodies for decades (22, 23) . Possible factors contributing to interassay variation include batch-to-batch variation in cell culture reagents, differences in cell passage number, and technician subjectivity in enumerating plaques. Future studies may wish to evaluate the difference in precision of a PRNT-75, which uses 75% neutralization of SARS-CoV-2 as a threshold for neutralization. In a previous study of dengue virus PRNT assays, PRNT-75 was identified as the optimal evaluation point with the least inter-and intraassay variance compared with that of assay thresholds from PRNT-40 to PRNT-90 (22) . To date, PRNT-50 and/or PRNT-90 are the most commonly used for the evaluation of SARS-CoV-2-neutralizing antibodies.

The validated PRNT was then used as a reference standard to compare several alternate PRNTs and sVNTs for SARS-CoV-2-neutralizing antibodies. Both of the alternate PRNTs conducted by U of A and Wadsworth demonstrated excellent interrater agreement with the reference-standard PRNT. The only difference between the two assays was their result for the laboratory-confirmed COVID-19 specimen that tested nAb2 by the reference standard. The specimen tested positive by an ELISA detecting anti-SARS-CoV-2 nucleocapsid IgA, IgM, and IgG antibodies (Platelia SARS-CoV-2 Total Ab assay, BIO-RAD). However, the specimen tested negative by anti-SARS-CoV-2 spike 1 ELISAs, including ZEUS ELISA SARS-CoV-2 IgG test system and Euroimmun anti-SARS-CoV-2 ELISA (IgG and IgA). While the U of A assay agreed with the reference standard, the Wadsworth assays deemed the specimen to be positive for SARS-CoV-2-neutralizing antibodies. This observation could be interpreted in 2 different ways. First, one could consider the Wadsworth assay to demonstrate sensitivity greater than that of the reference standard and U of A PRNTs for detecting nAbs in laboratory-confirmed COVID-19 specimens. This is supported by the positive results generated by the cVNT (BC CDC) and the luciferase-based sVNT (CRCHUM). The second interpretation could consider the reference standard and U of A PRNTs to have a higher threshold for neutralizing activity. This is supported by the specimen testing negative for antibodies against the SARS-CoV-2 spike 1, which contains the RBD targeted by the majority of nAbs. Further research is needed to establish the threshold of neutralizing activity in vitro that correlates with neutralization and protection in vivo. One difference was that heat inactivation of serological specimens was conducted for the reference standard and U of A assays but not for the Wadsworth assay. Heat inactivation of serum at 56°C for 30 min is standard procedure in order to inactivate complement when evaluating neutralization (24, 25) . Complement has been demonstrated to enhance in vitro neutralization of viruses, including human cytomegalovirus (26) , influenza virus (27), West Nile virus (28) , and hepatitis C virus pseudotypes (29), directly and/or by enhancement of antibody neutralization. A recent study demonstrated that heat-inactivating serum specimens prior to immunoanalysis resulted in significantly lower observed levels of IgM and IgG anti-SARS-CoV-2 antibodies by ELISA (30) . However, the effect was not characterized for PRNT and it remains unknown whether complement contributes to direct neutralization and/or enhancement of antibody-mediated neutralization in SARS-CoV-2 PRNT assays.

The other assays evaluated in this study demonstrate potential alternatives for the measurement of neutralizing antibodies against SARS-CoV-2. For example, aside from the alternate PRNTs, the cVNT (BC CDC) demonstrated the greatest interrater agreement with the reference-standard PRNT and offers practical benefits, such as a 96-well format to evaluate more samples per plate and decreased processing time due to the absence of a semisolid overlay step. However, like the PRNT, the cVNT still requires CL-3 facilities to manipulate live SARS-CoV-2 and analysis of neutralization can be affected by technician subjectivity. In contrast, the luciferase-based pseudotyped lentivirus sVNTs, the commercially available sVNT, and anti-RBD IgG ELISA are analyzed using automated platforms, decreasing processing time and observer subjectivity. In addition, these platforms can be conducted safely without a CL-3 facility, greatly expanding their use in lower-containment-level laboratories. However, cell-based assays, such as PRNT, cVNT, and luciferase-based pseudotyped lentivirus sVNTs, require highly skilled personnel and several days to conduct, hindering their practicality for use in large-scale immunity studies. While both anti-RBD IgG ELISAs and the commercially available sVNT are simple, high-throughput, and demonstrate excellent interrater agreement with the reference-standard PRNT, the anti-RBD IgG ELISA is a less expensive method to screen for the presence of potential neutralizing antibodies. Furthermore, the anti-RBD IgG ELISA has demonstrated near perfect agreement with another commercial sVNT (31) . Thus, this ELISA could be used as a more cost-effective alternative to the commercially available sVNT as a screening assay prior to confirmation by PRNT, similar to a previously proposed algorithm (32) .

It is crucial to recognize the small number of specimens in the panel used for the evaluation of these assays, which could limit the generalizability of the study. However, several of these protocols have been characterized further and demonstrated excellent performance in other studies (6, 7, (33) (34) (35) (36) (37) (38) . Importantly, our study demonstrates the proof-of-principle of using a sufficiently validated platform as a reference standard to directly compare nine serological methods to quantify and/or estimate the presence of neutralizing antibodies across several laboratories. Future evaluation of other alternate and surrogate platforms for the quantification of SARS-CoV-2-neutralizing antibodies will require a larger sample subset similar to the subset used for the validation of the reference-standard PRNT used in this study. Recently, the WHO has made recommendations to express serological data for neutralization in international units (IUs) as a way to effectively compare results of several studies (39) . This standardization of results should be used in future studies using any of the assays evaluated in this study, especially in clinical studies, where it is crucial to be able to draw comparisons between trials.

Ethics and biosafety statements. This study was approved by the Public Health Agency of Canada's Research Ethics Board (Protocol no. 2020-004P). All experiments involving SARS-CoV-2 (risk group 3 [RG-3]) were conducted in a containment level 3 (CL-3) laboratory. Procedures involving live SARS-CoV-2 were conducted using personal protective measures and operational practices for the manipulation of SARS-CoV-2 outlined by the Government of Canada (40) .

Cell line and virus. Vero E6 cells (CRL-1586; ATCC, Manassas, VA), HEK 293T cells (CRL-3216; ATCC), and HEK 293T-ACE2 cells were maintained in Dulbecco's modified Eagle's medium, high glucose with Lglutamine (DMEM; HyClone, San Angelo, TX) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco, Waltham, MA). The 293T-ACE2 has been described elsewhere (6) .

SARS-CoV-2 (hCoV-19/Canada/ON_ON-VIDO-01-2/2020, EPI_ISL_425177) p3 stocks were produced by infecting Vero E6 cells at a multiplicity of infection (MOI) of 0.1. After 1 h of adsorption at 37°C and 5% CO 2 , DMEM supplemented with 2% FBS was added and flasks were placed in a 37°C incubator in an atmosphere of 5% CO 2 . The flasks were monitored daily under a light microscope to detect the presence of cytopathic effect (CPE) in infected cells and lack of CPE in the mock-infected cells. After 72 h postinfection (HPI), virus supernatant was collected and centrifuged for 10 min at 525 Â g and 4°C to remove cell debris. Aliquots of SARS-CoV-2 were prepared and transferred to a 280°C freezer for long-term storage. SARS-CoV-2 stocks were titrated using a previously described plaque assay (41) .

Samples. Samples used for the validation of the reference standard SARS-CoV-2 PRNT were as follows: SARS-CoV-2 antibody-positive specimens comprised human serum and plasma samples from COVID-19 patients from Sunnybrook Hospital who were confirmed positive by molecular testing (Toronto Invasive Bacterial Diseases Network, ON; n = 218). All participants provided informed consent for collection of serum (Sinai Health Sytem REB no. 02118-U and no. 05-0016-C). The subset included 38, 60, 20, 16, 20, 22, 20 , and 21 specimens collected at 1 to 7, 8 to 14, 15 to 21, 22 to 28, 29 to 35, 36 to 42, 43 to 49, and $50 days post-symptom onset. Of these samples, 24 were used for evaluating intraassay precision and 18 of these samples were used for evaluating interassay precision of the reference-standard PRNT. SARS-CoV-2 antibody-negative human serum samples were obtained from healthy adults prior to the COVID-19 pandemic (n = 52). The sample subset used for the multilaboratory comparison of alternative and surrogate platforms for the detection of SARS-CoV-2 were as follows: 19 specimens collected from laboratory-confirmed COVID-19 patients and confirmed positive for neutralizing antibody by reference standard SARS-CoV-2 PRNT (COVID-19 nAb1) and 1 specimen collected from molecularly confirmed COVID-19 patients and confirmed negative for neutralizing antibody negative by referencestandard PRNT (COVID-19 nAb2). In addition, the panel comprised laboratory-confirmed specimens from 2 SARS-CoV-1 patients, 5 hepatitis patients, 5 syphilis patients, and 3 HIV patients, as well as 5 specimens from healthy individuals collected prior to the COVID-19 pandemic. The latter were collected from individuals whose occupations required routine quantification of anti-rabies virus-neutralizing antibody titers postvaccination.

SARS-CoV-2 plaque-reduction neutralization test. The SARS-CoV-2 PRNT was adapted from a previously described method for SARS-CoV-1 (42) . Serological specimens were diluted 1:10 in DMEM supplemented with 2% FBS and inactivated at 56°C for 30 min. In a 96-well plate, sera were further diluted 2-fold from 1:10 to 1:640 in DMEM supplemented with 2% FBS in a volume of 150 mL. One hundred fifty microliters of SARS-CoV-2 diluted at 100 PFU/100 mL was added to each well, yielding final serum dilutions of 1:20 to 1:1,280 and final virus concentrations of 50 PFU/100 mL. No neutralization, 50% neutralization, and 90% neutralization controls were prepared by diluting SARS-CoV-2 at 50 PFU/100 mL, 25 PFU/100 mL, and 5 PFU/100 mL, respectively. These were incubated with no sera. DMEM supplemented with 2% FBS was used as a no-virus control. After 1 h of incubation at 37°C and 5% CO 2 , 100 mL of each sera-virus mixture containing 50 PFU of SARS-CoV-2 was added in duplicate to 12-well plates containing Vero E6 cells at 95 to 100% confluence. One hundred microliters of each control was added in triplicate to two sets of 12-well plates containing Vero E6 cells. All plates were incubated at 37°C and 5% CO 2 for 1 h. After adsorption, a liquid overlay was prepared by adding equal volumes of 3% carboxymethylcellulose (CMC) and 2Â modified Eagle's medium (Temin's modification), no phenol red (2Â MEM; Gibco, Waltham, MA) supplemented with 8% FBS, 4 mM L-glutamine, 2Â nonessential amino acids, and 1.5% sodium bicarbonate. A total of 1.5 mL of liquid overlay was added to each well and plates were incubated at 37°C and 5% CO 2 for 3 days. The liquid overlay was removed and cells were fixed with 10% neutral buffered formalin for 1 h at room temperature. The monolayer in each well was stained with 100 mL 0.5% crystal violet (wt/vol) in 20% ethanol for 10 min and washed with 20% ethanol. For each specimen, the average number of plaques was calculated for each dilution and compared with the average number of plaques for 50% neutralization and 90% neutralization controls. The reciprocal of the highest serum dilution resulting in 50% and 90% reduction in plaques compared with controls was defined as the PRNT-50 and PRNT-90 endpoint titer, respectively. PRNT-50 titers and PRNT-90 titers of $20 were considered positive for SARS-CoV-2-neutralizing antibodies, whereas titers of ,20 were considered negative for SARS-CoV-2-neutralizing antibodies. Under the assumption that these specimens are negative for neutralizing antibodies, these specimens have a value of 0 for statistical analysis purposes.

Validation of reference standard SARS-CoV-2 PRNT. Following guidelines outlined by the World Health Organization (https://www.who.int/medicines/areas/quality_safety/quality_assurance/28092018Guideline_ Validation_AnalyticalMethodValidation-Appendix4_QAS16-671.pdf), the precision, accuracy, and specificity of the SARS-CoV-2 PRNT were assessed using both PRNT-50 and PRNT-90 titers. The intraassay precision of the PRNT was defined as the agreement of results generated by a single assay for the same homogenous sample. Intraassay precision was assessed by testing samples collected from laboratory-confirmed SARS-CoV-2 patients (n = 24) in triplicate in a single assay run. The interassay precision of the PRNT was defined as the agreement of results generated by several assays for the same homogenous sample. Interassay precision was assessed by testing samples collected from laboratory-confirmed SARS-CoV-2 patients (n = 18) in three independent assay runs by three different analysts. Intraassay and interassay precision were considered acceptable if $90% of the observed results were within 4-fold difference of the median titer for $80% of positive samples tested. For both intra-and interassay validations, the sample subset comprised high-volume specimens representing a variety of PRNT titers. Samples collected from laboratory-confirmed SARS-CoV-2 patients were used even if negative for SARS-CoV-2-neutralizing antibody; this was to ensure that even negative results were congruent within and between assay runs. Accuracy of the PRNT was defined as the degree of agreement of test results with the true value. Accuracy was assessed by testing laboratory-confirmed SARS-CoV-2 undiluted and diluted at 1:4, 1:16, and 1:64 in PBS 5 times each within the same assay run. The expected titer for each diluted specimen was defined as the mean of the four observed titers for the corresponding undiluted specimen divided by the dilution factor (4, 16, and 64, respectively). Accuracy was considered acceptable if the absolute difference of the log 2 observed mean titer and the log 2 expected titer was #2.00 for $80% results for each dilution. Specificity of the PRNT was defined as the percentage of SARS-CoV-2 antibody-negative samples from healthy individuals collected prior to the COVID-19 pandemic, which tested negative in the assay. A specificity of $95% was considered acceptable.

Alternate PRNTs. Alternate PRNTs were conducted by Wadsworth Centre (New York, NY, USA) and the University of Alberta (Edmonton, AB, Canada; REB Pro00099761). These assays were conducted similarly to the reference-standard PRNT, with a few distinct differences in SARS-CoV-2 stock production, virus dilution, challenge and adsorption, overlay, and visualization. These differences are summarized in Table 5 .

SARS-CoV-2 microneutralization test: cVNT. A cell culture-based SARS-CoV-2 microneutralization test was developed and conducted in a CL-3 facility at the British Columbia Centre for Disease Control (BC CDC). Sera were incubated at 56°C for 30 min to inactivate the complement. Each serum was subjected in duplicate to 2-fold serial dilution from 1:8 to 1:4,096 in volumes of 100 microliters in a 96-well microtiter plate. To each dilution, 100 50% tissue culture infective dose (TCID 50 ) units of SARS-CoV-2 were added in a 50-mL volume and the preparations were incubated at 37°C for 2 h. Volumes of 100 mL of each dilution were inoculated into respective wells of a microtiter plate containing monolayers of Vero-E6 cells in MEM containing 2% fetal bovine serum. The cultures were incubated at 37°C in a CO 2 incubator and examined after 72 h for the development of characteristic cytopathic effect. The reciprocal dilution below the one at which cytopathic effect could be detected was deemed the titer of neutralizing antibody. Titers of $8 were considered positive for SARS-CoV-2-neutralizing antibodies, whereas titers of ,8 were considered negative for SARS-CoV-2-neutralizing antibodies. For each assay, previously tested sera were used as positive and negative controls.

Luciferase-based lentiviral sVNTs. Luciferase-based sVNTs using recombinant lentiviruses expressing SARS-CoV-2 spike were conducted by McGill University (Montreal, QC, Canada), Centre de recherche du CHUM (Montreal, QC, Canada), and Mount Sinai Hospital (Toronto, ON, Canada). Differences between these assays are summarized in Table 6 .

McGill University. The SARS-CoV-2 spike (S) protein pseudotyped lenti-Luc virus was produced by transfecting HEK293T cells in a 10-cm dish with 3 mg of pSPAX2 (Addgene, 12260), 6 mg of Lent-Luc (Addgene,17477), and 3 mg of SARS-CoV-2 S (provided by Shan Cen, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences) plasmid DNA using PEI (polyethylenimine). Forty hours posttransfection (HPT), viruses in the culture supernatants were collected, clarified by centrifugation at 3,000 rpm (Beckman GR-6S centrifuge) at 4°C to remove cell debris, and aliquoted, stored at 280°C. The quantity of virus stock was determined by measuring the copy number of viral RNA with reverse transcriptase-quantitative PCR (FRT-qPCR). The infectivity of the virus stock was measured by infecting HEK293T cells engineered to express ACE2 protein. The serological samples were first inactivated at 56°C for 30 min, then diluted in 100 ml DMEM containing 2% FBS in 5-fold from 1:2.5 to 1:1,562.5, mixed with 100 ml of lenti-Luc-SARS-CoV-2-S pseudotyped virus (8 Â 10 4 copies of viral RNA, diluted in DMEM with 2% FBS). After incubation for 1 h at 37°C and 5% CO 2 , virus/serum mixture was added to HEK293T-ACE2 cells that were seeded in a 96-well plate 1 day prior to infection (18,000 cells/ well). Each serum dilution was tested in three independent infections. After 2 h infection, virus/serum inoculum was replaced with 100 ml DMEM containing 10% FBS. Cells were cultured for 48 h at 37°C and 5% CO 2 , and then 100 ml of 2Â luciferase substrate (Steady-Glo luciferase assay system, Promega) was added for 20 min to lyse cells. Luciferase activity was measured with PerkinElmer EnSpire multimode plate reader. Luciferase values of infection without exposure to patient serum serve as the control infection. Fifty percent plaque-reduction/neutralization titer (PRNT 50 ) values were calculated using the GraphPad Prism software. A sample with a half-maximal inhibitory dilution (ID 50 ) of ,1:2.5 was considered "negative" and $1:2.5 was considered "positive" for SARS-CoV-2-neutralizing antibodies.

CRCHUM. The luciferase-based lentiviral sVNT was conducted as described previously (6) . Singleround lentivirus particles expressing SARS-CoV-2 spike and luciferase were rescued by calcium phosphate transfection of 293T cells with the lentiviral vector pNL4. .8], 1 mM ATP, and 1 mM dithiothreitol) and 50 mL of 1 mM D-luciferin potassium salt (Prolume). The neutralization half-maximal inhibitory dilution (ID 50 ) was determined using a normalized nonlinear regression and represents the plasma dilution to inhibit 50% of the infection of 293T-ACE2 cells by recombinant virus. A sample with an ID 50 of ,1:50 was considered negative and $1:50 was considered positive for SARS-CoV-2-neutralizing antibodies. Mount Sinai. The luciferase-based lentiviral sVNT was conducted as described previously (34, 35) . Lentivirus particles were rescued from HEK293T cells in a 6-well plate containing 2 mL growth medium (10% FBS, 1% penicillin/streptomycin [pen/strep] in DMEM). Cells were transiently cotransfected with 1.3 mg psPAX2 (Addgene, 12260), 1.3 mg pHAGE-CMV-Luc2-IRES-ZsGreen-W (BEI, NR-52516), and 0.4 mg HDM-IDTSpike-fixK (BEI, NR-52514) using 8 mL JetPrime (Polyplus-transfection SA, 114-01) in 500 mL JetPrime buffer. After 8 HPT, the medium was replaced by 3 mL of DMEM containing 5% heat-inactivated FBS and 1% pen/strep, and the cells were incubated for 16 h at 37°C and 5% CO 2 . Cells were then transferred to 33°C and 5% CO 2 for an additional 24 h. At 48 HPT, the supernatant was collected, centrifuged at 500 Â g for 5 min at room temperature, filtered through a 0.45-mm filter, and frozen at 280°C until use. For the neutralization assay, 2.5-fold serial dilutions of the serum samples were incubated with diluted virus at a 1:1 ratio for 1 h at 37°C before being transferred to plated HEK293-ACE2/TMPRSS2 cells and incubated for an additional 48 h at 37°C and 5% CO 2 . After 48 h, cells were lysed, and Bright-Glo luciferase reagent (Promega, E2620) was added for 2 min before reading with a PerkinElmer Envision instrument. A sample with an ID 50 of ,10 21.5 was considered negative and $10 21.5 was considered positive for SARS-CoV-2-neutralizing antibodies.

Commercially available hACE2 receptor-blocking antibody assay. The commercially available SARS-CoV-2 sVNT (L00847; GenScript, Piscataway, USA) was performed according to the manufacturer's instructions at McGill University (Montreal, QC, Canada). Briefly, serological specimens were incubated with horseradish peroxidase-conjugated RBD (HRP-RBD) at 37°C for 30 min. The mixtures were added to the hACE2-coated capture plate and incubated at 37°C for 15 min. Plates were then washed, removing HRP-RBD-neutralizing antibody complexes and allowing unbound HRP-RBD and HRP-RBD-nonneutralizing antibody complexes to remain bound to hACE2. 3,39,5,59-Tetramethylbenzidine (TMB) solution was added and allowed to incubate at room temperature for 15 min, and the reaction was stopped by stop solution. The optical density (OD) of each well was measured by spectrophotometry at 450 nm. The 

The flow cytometrybased assay evaluated in this study was developed and conducted by CRCHUM as described previously (43). Briefly, HEK293T cells transfected with an expression plasmid for the SARS-CoV-2 spike were stained with serological specimens diluted at 1:250. Transfected cells were stained with anti-RBD-Cr3002 monoclonal antibody diluted at 5 mg/mL as a positive control. Alexa Fluor-647-conjugated goat anti-human IgG (H1L) (Invitrogen, Rockford, IL) was used as a secondary antibody to detect IgG bound to SARS-CoV-2 spike. An LSRII cytometer (BD Biosciences, Mississauga, ON, Canada) was used to acquire the specimens. FlowJo v10.5.3 (Tree Star, Ashland, OR) was used for data analysis. A specimen was considered positive for nAbs if the proportion of cells bound by anti-spike antibodies was greater than the seropositivity threshold, which was calculated as the mean median fluorescence intensity (MFI) of all COVID-19-negative

Briefly, recombinant SARS-CoV-2 S RBD protein (2.5 mg/mL), or bovine serum albumin (BSA) (2.5 mg/mL) as a negative control, was prepared in phosphate-buffered saline (PBS) and adsorbed to plates (MaxiSorp Nunc) overnight at 4°C. Coated wells were subsequently blocked with blocking buffer (Tris-buffered saline [TBS] containing 0.1% Tween 20 and 2% BSA) for 1 h at room temperature. Wells were then washed four times with washing buffer

Signal obtained with BSA was subtracted for each plasma and was then normalized to the signal obtained with CR3022 present in each plate. Statistical analyses. A two-way analysis of variance (ANOVA) with Tukey multiple comparison posttest was conducted to analyze the relationship between reciprocal endpoint neutralizing antibody titers and time of collection post-symptom onset in the laboratory-confirmed COVID-19 patient subset. Results generated from alternative conventional and surrogate SARS-CoV-2 neutralization tests were categorized as either positive or negative for SARS-CoV-2-neutralizing antibodies as described above. Congruence was defined as the percentage of results generated by the assay in agreement with the results generated by the reference PRNT. Number of results in agreement with the reference PRNT is indicated in parentheses. Two-tailed Fisher's exact tests were conducted to analyze the congruence between alternate/surrogate SARS-CoV-2 neutralization tests compared with the reference standard SARS-CoV-2 PRNT. Kappa values (k -values) as a measure of interrater agreement between alternative conventional and surrogate SARS-CoV-2 neutralization tests and the reference standard SARS-CoV-2 PRNT were also calculated using this software. Assays yielding k -values between ,0 and 1.00 indicate no agreement and perfect agreement

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Asymptomatic transmission, the Achilles' heel of current strategies to control Covid-19

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset

Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike

Decline of humoral responses against sars-cov-2 spike in convalescent individuals

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

Evolution of antibody immunity to SARS-CoV-2

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

A review of SARS-CoV-2 and the ongoing clinical trials

Pharmacologic treatments for coronavirus disease 2019 (COVID-19)

Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance

Evaluation of nine commercial SARS-CoV-2 immunoassays

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Stamatatos L. 2021. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-191 subjects

Neutralizing antibody titres in SARS-CoV-2 infections

Variability in Dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development

Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis

Neutralization of animal viruses

Neutralization of virus infectivity by antibodies: old problems in new perspectives

Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (Gb) and immune sera induced by Gb/MF59 vaccination

Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity

Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus

Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C vVirus E2 chimeric glycoprotein

Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS-CoV-2

Evaluation of a commercial culture-free neutralization antibody detection kit for severe acute respiratory syndrome-related coronavirus-2 and comparison with an anti-RBD ELISA assay

Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Antibody binding to SARS-CoV-2 S glycoprotein correlates with but does not predict neutralization

Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays

A simple protein-based surrogate neutralization assay for SARS-CoV-2

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2

Identification of SARS-CoV-2-specific immune alterations in acutely ill patients

Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles

WHO international standard for anti-SARS-CoV-2 immunoglobulin

Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2). Government of Canada

Two detailed plaque assay protocols for the quantification of infectious SARS-CoV-2

Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV)

High-throughput detection of antibodies targeting the SARS-CoV-2 spike in longitudinal convalescent plasma samples

The measurement of observer agreement for categorical data

This project was supported by the Public Health Agency of Canada (PHAC). We thank Darwyn Kobasa, Amrit Boese, and Anders Leung for providing the SARS-CoV-2 stock (PHAC), as well as Lise Lamoureux, Elizabeth McLachlan, Antonia Dibernardo, and Robbin Lindsay (PHAC) for their assistance during this study. We also thank Todd Hatchette (Nova Scotia Health Authority), John Kim (PHAC), Tim Booth (PHAC), and Vanessa Tran (Public Health Ontario) for providing serological specimens for cross-reactivity studies. Work at CHUM was supported by le Ministère de l' Economie et de l'Innovation du Québec, Program de soutien aux organismes de recherche et d'innovation to A.F. and by the Fondation du CHUM. This work was also supported by a CIHR foundation grant no. 352417 to A.F. and by an Exceptional Fund COVID-19 from the Canada Foundation for Innovation (CFI) no. 41027 to A.F. A.F. is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. R.G. is supported by a MITACS Accélération postdoctoral fellowship. The authors are grateful to the donors who participated in this study. We thank Stefan Pöhlmann (Georg-August University, Germany) for the plasmid coding for SARS-CoV-2 and M. Gordon Joyce (U.S. MHRP) for the monoclonal antibody CR3022.